Clinical pathways of breast cancer patients treated in the Federal District, Brazil

被引:0
|
作者
Barros, Angela Ferreira [1 ,2 ]
de Araujo, Jeniffer Melo [3 ]
Murta-Nascimento, Cristiane [4 ]
Dias, Adriano [4 ]
机构
[1] Secretaria Estado Saude Dist Fed, Escola Super Ciencias Saude, Brasilia, DF, Brazil
[2] Univ Estadual Paulista, Fac Med, Programa Posgrad Saude Colet, Botucatu, SP, Brazil
[3] Hosp Alvorada Brasilia, Brasilia, DF, Brazil
[4] Univ Estadual Paulista, Fac Med, Programa Posgrad Saude Colet, Dept Saude Publ, Botucatu, SP, Brazil
来源
REVISTA DE SAUDE PUBLICA | 2019年 / 53卷
关键词
Breast Neoplasms; therapy; Time-to-Treatment; Health Care Quality; Access; and Evaluation; Health Status Disparities; Health Services Accessibility; ACCESS; MANAGEMENT; DIAGNOSIS; COUNTRIES; SURVIVAL; EQUITY; SYSTEM; DELAY; TIME;
D O I
10.11606/S1518-8787.2019053000406
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To identify the clinical pathways of women with breast cancer treated in public hospitals, and to analyze the factors that influence the time interval between the first appointment and the start of therapy. METHODS: A cross-sectional study was conducted with 600 women with breast cancer treated in nine public hospitals in the Brazilian Federal District. Patients were interviewed between September 2012 and September 2014. Simple and multiple logistic regression models were adjusted to evaluate the variables associated with the time interval studied. The most frequent pathway was the one that started in primary care with following care in the therapy service (28.9%). In the multiple adjustment, factors associated to a longer time interval between the first appointment and therapy were: lower family income (OR = 1.89; 95% CI 1.32-2.68), the first appointment in public services (OR = 1.78; 95% CI 1.20-2.64), care in more than two health services in the clinical pathway (OR = 1.71; 95% CI 1.19-2.44); and obtaining the anatomopathological analysis of the biopsy in public services instead of private health services (OR = 1.87; 95% CI 1.29-2.71). Independently, the implementation of specialist appointment scheduling, with care regulation, was associated with a shorter time interval between first appointment and therapy (OR = 0.33; 95% CI 0.16-0.65). CONCLUSIONS: We observed that multiple pathways were covered by women with breast cancer treated in public services of the Federal District. Socioeconomic iniquities and several aspectos of the pathways covered were associated with a longer time interval between the first appointment and the start of breast cancer therapy.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Floristic composition of a conservation area in the Federal District of Brazil
    Silva, Juliana Silvestre
    Felfili, Jeanine Maria
    BRAZILIAN JOURNAL OF BOTANY, 2012, 35 (04) : 385 - 395
  • [32] Autochthonous visceral leishmaniasis in Brasilia, Federal District, Brazil
    Carranza-Tamayo, Cesar Omar
    Laurentino de Carvalho, Maria do Socorro
    Bredt, Angelika
    Rao Bofil, Maria Isabel
    Barreto Rodrigues, Rodrigo Menna
    da Silva, Ailton Domicio
    Felipe Coelho Cortez, Sandra Maria
    Sierra Romero, Gustavo Adolfo
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2010, 43 (04) : 396 - 399
  • [33] Mercury in breast milk from women in the Federal District, Brazil and dietary risk assessment for breastfed infants
    Rebelo, Fernanda M.
    da Cunha, Leandro R.
    Andrade, Patricia D.
    da Costa Junior, Walkimar A.
    Bastos, Wanderley R.
    Caldas, Eloisa D.
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2017, 44 : 99 - 103
  • [34] Molecular network analysis of signaling pathways in metastatic breast cancer in patients treated with erlotinib.
    Speer, R.
    Wallwiener, D.
    Yang, S. X.
    Swain, S. M.
    Wulfkuhle, J. D.
    Liotta, L. A.
    Petricoin, E. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 556S - 556S
  • [35] The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab
    Grell, P.
    Svoboda, M.
    Fabian, P.
    Radova, L.
    Dziechciarkova, M.
    Palacova, M.
    Nenutil, R.
    Hajduch, M.
    Vyzula, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
    Weiss, Jennifer A.
    Nicklawsky, Andrew
    Kagihara, Jodi A.
    Gao, Dexiang
    Fisher, Christine
    Elias, Anthony
    Borges, Virginia F.
    Kabos, Peter
    Davis, Sarah L.
    Leong, Stephen
    Eckhardt, Sue Gail
    Diamond, Jennifer R.
    CANCER MEDICINE, 2020, 9 (23): : 8801 - 8808
  • [37] Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Keam, Bhumsuk
    Im, Seock-Ah
    Park, Sohee
    Nam, Byung-Ho
    Han, Sae-Won
    Oh, Do-Youn
    Kim, Jee Hyun
    Lee, Se-Hoon
    Han, Wonshik
    Kim, Dong-Wan
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    Heo, Dae Seog
    Bang, Yung-Jue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (09) : 1301 - 1308
  • [38] Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen
    Scarpi, E
    De Paola, F
    Sarti, M
    Bajorko, P
    Granato, AM
    Volpi, A
    Nanni, O
    Maltoni, R
    Amadori, D
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 68 (02) : 101 - 110
  • [39] Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Keam, B.
    Im, S. -A.
    Park, S.
    Nam, B. -H.
    Han, S. -W.
    Oh, D. -Y.
    Han, W.
    Kim, T. -Y.
    Park, I. A.
    Noh, D. -Y.
    BREAST, 2011, 20 : S76 - S76
  • [40] Clinical course of breast cancer patients with liver metastases only treated with chemotherapy
    Er, Ozlem
    Frye, Debbie
    Broglio, Kristine
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Arun, Banu
    ANNALS OF ONCOLOGY, 2004, 15 : 46 - 46